Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine + lixisenatide fixed-ratio combination versus insulin glargine in adults with type 2 diabetes
NL-OMON40160Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Sep 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine, lixisenatide and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline at week 30. Started Sep 2014; status: active, not recruiting.
02
Drugs
insulin glarginelixisenatidemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40160.